BioSpace News Archive

Societal CDMO, Inc. announced that it has been selected by AmyriAD Pharma to provide CDMO services to support the ongoing clinical development of AD101.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,345,896 to the Company on May 31, 2022.

Kamada Ltd. announced that it will host a virtual analysts and investors meeting on Tuesday, June 7, 2022, at 12:00 PM Eastern Time to review its growth catalysts.

Apellis Pharmaceuticals, Inc. announced that the company has submitted a New Drug Application to the United States Food and Drug Administration for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis, a pre-clinical model of rheumatoid arthritis, at the EULAR 2022 Congress in Copenhagen, Denmark.

Rezolute, Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer.

IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 3:00 p.m. EST in New York.

Axsome Therapeutics, Inc. announced positive results from the long-term, open-label EVOLVE trial of AXS-05 in major depressive disorder.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will present at the following investor conferences.

Hoffmann-La Roche Limited is pleased to announce that Health Canada authorized VABYSMO® for the treatment of neovascular age-related macular degeneration and diabetic macular edema, two of the leading causes of vision loss among Canadians.